Daily Cosmetic Research Analysis
Analyzed 1 papers and selected 1 impactful papers.
Summary
Today's literature includes expert recommendations for diagnosing and managing chronic hand eczema (CHE) in the United States. The article proposes a structured, multi-step care pathway, highlights topical delgocitinib as the only FDA-approved therapy for CHE after topical steroid inadequacy, and emphasizes clinician- and patient-reported outcomes.
Research Themes
- Structured diagnostic and treatment algorithms for chronic hand eczema
- Regulatory and coding gaps impacting CHE care (FDA approval, ICD-10 coding)
- Integration of clinician- and patient-reported outcomes in dermatology
Selected Articles
1. Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.
This expert consensus outlines a practical diagnostic workup centered on detailed history and examination, followed by a multi-step treatment pathway for chronic hand eczema in the U.S. It highlights topical delgocitinib as the only FDA-approved therapy for patients inadequately controlled with topical corticosteroids and stresses incorporating clinician- and patient-reported outcomes to capture disease burden and quality-of-life impact.
Impact: It fills a critical gap in U.S.-specific guidance for chronic hand eczema by proposing an actionable care pathway and clarifying the role of the only FDA-approved agent, topical delgocitinib. Emphasizing standardized outcome measures can harmonize care and research.
Clinical Implications: Adopting a structured, stepwise algorithm may improve consistency in CHE care; clinicians should consider topical delgocitinib when topical corticosteroids are inadequate or unsuitable. Routine use of clinician- and patient-reported outcomes can better capture severity and quality-of-life impact and inform treatment adjustments.
Key Findings
- Defines CHE and emphasizes diagnostic assessment via detailed history and physical examination.
- Proposes a multi-step treatment approach to standardize CHE management.
- Identifies topical delgocitinib as the only FDA-approved therapy for CHE after inadequate response to topical corticosteroids.
- Stresses the importance of clinician- and patient-reported outcomes to capture severity and quality-of-life impact.
Methodological Strengths
- Provides a clear, stepwise clinical framework for diagnosis and treatment.
- Explicit emphasis on both clinician- and patient-reported outcomes to guide care.
Limitations
- Lack of a standardized classification system for CHE complicates diagnosis and cross-study comparability.
- Absence of specific ICD-10 codes in the U.S. hinders tracking of diagnoses and treatments.
Future Directions: Develop and validate a standardized classification system and U.S.-specific ICD-10 codes; conduct comparative effectiveness trials and real-world studies evaluating stepwise algorithms and topical delgocitinib across CHE subtypes.
Chronic hand eczema (CHE) is an inflammatory skin disease localized to the hands and wrists that lasts for more than 3 months or relapses at least twice per year. The diagnosis, treatment, and management of CHE presents clinical challenges owing to its multifactorial etiology, heterogeneous presentation, and the absence of a standardized classification system. In the USA there are no specific International Classification of Disease-10 (ICD-10) diagnostic codes, which makes tracking the diagnosis and resultant treatments difficult. Topical delgocitinib is currently the only Food and Drug Administration approved medication for CHE, for patients who have not responded adequately to, or are unable to use, topical corticosteroids. This article provides an overview of the diagnostic and therapeutic considerations of CHE, while presenting practical recommendations to help improve management of the disease within the USA. Diagnostic assessments focusing on detailed patient history and physical examination are proposed, followed by a multi-step approach to treatment. The importance of both clinician, and patient, reported outcome measures are emphasized, to encompass not only disease presentation and severity, but also the impact on patient quality of life.